Viking Therapeutics Shares Surge 13% in Pre-Market Trade

Shares of Viking Therapeutics (VKTX) rose 12% in pre-market trading after the company said a study of VK2809 in an in vivo model of non-alcoholic steatohepatitis (NASH) demonstrated improvements across several key measures relevant to the development and progression of the disease.

Animals receiving VK2809 experienced statistically significant improvements in non-alcoholic fatty liver disease activity score (NAS), liver collagen content, and liver fibrosis relative to vehicle-treated controls.

NASH is a composite measure of disease activity which is comprised of steatosis, ballooning and inflammation. Viking said the results represent the first evidence of a thyromimetic agent providing histologic benefits in a NASH model, including an improvement in fibrosis.

Leave a Comment